UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, ~~2019~~2020


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. ~~001‑38535~~001-38535

Aptinyx Inc.

(Exact name of registrant as specified in its charter)


Delaware		47-4626057
~~Delaware~~		~~47‑4626057~~
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

909 Davis Street, Suite 600

Evanston, IL 60201

(847) ~~871‑0377~~871-0377

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	APTX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule ~~12b‑2~~12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule ~~12b‑2~~12b-2 of the Exchange Act). Yes ☐ No ☒

As of November ~~8, 2019,~~6, 2020 the registrant had ~~33,679,965~~63,256,689 shares of common stock, $0.01 par value per share, outstanding.

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form ~~10‑Q~~10-Q contains forward-looking statements that involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. All statements, other than statements of historical facts, contained in this Quarterly Report on Form ~~10‑Q,~~10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” ~~“would”~~“would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements include, among other things, statements about:

●

the timing, progress, and results of preclinical studies and clinical trials for ~~NYX‑2925, NYX‑783,~~NYX-2925, NYX-783, NYX-458, and any future product candidates we may develop, including statements regarding the timing of initiation, recommencement, and completion of studies or trials and related preparatory work, and costs associated therewith, the period during which the results of the studies will become available, ~~and~~ our research and development ~~programs;~~

programs, and our ability to demonstrate safety and efficacy of our product candidates to the satisfaction of applicable regulatory authorities;

●

the impacts of the current COVID-19 pandemic on our continuing operations, clinical development plans, including the timing of initiation, recommencement and completion of studies or trials, financial forecasts and expectations, and other matters related to our business and operations;

●

the existence or absence of side effects or other properties relating to our product candidates ~~which~~that could delay or prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences following any potential marketing approval;

●

the potential for our identified research priorities to advance our technologies;

●

the potential ~~timelines for our clinical studies or~~benefits of, and our ability to ~~demonstrate safety~~maintain, our collaboration with Allergan plc, or Allergan, and ~~efficacy of~~ our ~~product candidates~~ability to ~~the satisfaction of applicable regulatory authorities;~~

establish or maintain future collaborations or strategic relationships or obtain additional funding in connection with these relationships;

●

our ability to obtain and maintain regulatory approval of our product candidates, NYX-2925, NYX-783, NYX-458, and any other future product candidates, and any statements regarding the label of an approved product candidate, including any restrictions, limitations, and/or warnings therein;

●

our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering NYX-2925, NYX-783, NYX-458, and any additional product candidates we may develop, and any statements as to whether we do or do not infringe, misappropriate, or otherwise violate any third-party intellectual property rights;

●

our ability and the potential to successfully manufacture our product candidates for clinical studies and for commercial use, if approved;

●

our ability to commercialize our products in light of the intellectual property rights of others;

●

our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;

●

our plans to research, develop, and commercialize our product candidates;

●

our ability to ~~retain and~~ attract collaborators with ~~research,~~ development, regulatory, and commercialization expertise;

●

the size and growth potential of the markets for our product candidates and our ability to serve those markets;

●

the rate and degree of market acceptance and clinical utility of ~~NYX‑2925,~~NYX-2925, NYX-783, ~~NYX‑458,~~NYX-458, and any future product candidates we may develop, if approved;

●

the pricing and reimbursement of ~~NYX‑2925, NYX‑783, NYX‑458,~~NYX-2925, NYX-783, NYX-458, and any future product candidates we may develop, if approved;

●

regulatory developments in the United States and foreign countries;

●

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

●

the success of competing therapies that are or may become available;

Table of Contents

●

our ability to retain the continued service of our key professionals and to identify, hire, and retain additional qualified professionals;

●

the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;

●

our financial performance;

●

our expectations related to the use of our cash reserves;

~~Table of Contents~~

●

the impact of laws and regulations, including, without limitation, recently enacted tax reform legislation;

●

~~the use of proceeds from our initial public offering;~~

our expectations regarding the time during which we will be an “emerging growth company” under the Jumpstart Our Business Startups Act; ~~and~~

●

our use of proceeds from the initial and follow-on public offering; and

●

other risks and uncertainties, including those listed under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, or Annual Report.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q and our Annual Report filed with the Securities and Exchange Commission, or the SEC, on March ~~21, 2019,~~30, 2020, particularly in the “Risk Factors” section, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or into which we may enter.

You should read this Quarterly Report on Form ~~10‑Q~~10-Q and the documents that we reference herein and have filed or incorporated by reference as exhibits hereto completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Condensed Financial Statements.

Aptinyx Inc.

Condensed Balance Sheets

(unaudited)

(Inin thousands, except per share data)


	September 30,		December 31,
	2019		2018

					September 30,		December 31,
					2020		2019
Assets
Current assets:
Cash and cash equivalents	$	114,214	$	150,637	$	103,810	$	98,849
Restricted cash		179		252		179		179
Accounts receivable		461		578		257		444
Prepaid expenses and other current assets		3,980		1,784		8,836		5,637
Total current assets		118,834		153,251		113,082		105,109
Other assets		166		673		92		166
Property and equipment, net		1,330		1,690		1,033		1,204
Total assets	$	120,330	$	155,614	$	114,207	$	106,479
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,750	$	1,889	$	986	$	1,555
Accrued expenses and other current liabilities		5,344		3,996		3,281		3,341
Total current liabilities		7,094		5,885		4,267		4,896
Other long-term liabilities		309		418		154		272
Total liabilities	$	7,403	$	6,303	$	4,421	$	5,168
Commitments and contingencies (see Note 10)
Stockholders’ equity:
Preferred stock, $0.01 par value, 10,000 shares authorized and no shares issued and outstanding as of September 30, 2019 and December 31, 2018		—		—
Common stock, $0.01 par value, 150,000 shares authorized as of September 30, 2019 and December 31, 2018, 33,676 and 33,341 issued and outstanding as of September 30, 2019 and December 31, 2018		337		333
Preferred stock, $0.01 par value, 10,000 shares authorized and no shares issued and outstanding as of September 30, 2020 and December 31, 2019						—		—
Common stock, $0.01 par value, 150,000 shares authorized as of September 30, 2020 and December 31, 2019, 47,157 and 33,739 issued and outstanding as of September 30, 2020 and December 31, 2019						471		337
Additional paid-in capital		261,760		254,516		310,828		263,922
Accumulated deficit		(149,170)		(105,538)		(201,513)		(162,948)
Total stockholders’ equity	$	112,927	$	149,311	$	109,786	$	101,311
Total liabilities and stockholders’ equity	$	120,330	$	155,614	$	114,207	$	106,479

See accompanying notes to these unaudited condensed financial statements.

Table of Contents

Aptinyx Inc.

Condensed Statements of Operations

(unaudited)

(Inin thousands, except per share data)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018


									Three Months Ended September 30,				Nine Months Ended September 30,
									2020		2019		2020		2019
Revenues:
Collaboration revenue		936		943	$	2,751	$	3,893	$	257	$	936	$	1,564	$	2,751
Grant revenue		—		—		—		1,642
Total revenues	$	936	$	943		2,751		5,535
Operating expenses:
Research and development		11,761		11,950		33,732		37,860		6,630		11,761		26,049		33,732
General and administrative		4,523		3,782		14,419		7,853		5,050		4,523		14,719		14,419
Total operating expenses		16,284		15,732		48,151		45,713		11,680		16,284		40,768		48,151
Loss from operations		(15,348)		(14,789)		(45,400)		(40,178)		(11,423)		(15,348)		(39,204)		(45,400)
Other income		558		608		1,768		990		85		558		639		1,768
Net loss and comprehensive loss	$	(14,790)	$	(14,181)	$	(43,632)	$	(39,188)	$	(11,338)	$	(14,790)	$	(38,565)	$	(43,632)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.44)	$	(0.43)	$	(1.30)	$	(2.48)	$	(0.24)	$	(0.44)	$	(0.85)	$	(1.30)
Weighted-average number of common shares outstanding, basic and diluted		33,646		33,191		33,510		15,789		46,978		33,646		45,503		33,510

See accompanying notes to these unaudited condensed financial statements.

Table of Contents

Aptinyx Inc.

Condensed Statements of Cash Flows

(unaudited)

(Inin thousands)


	Nine Months Ended
	September 30,
	2019		2018

					Nine Months Ended
					September 30,
					2020		2019
Cash flows from operating activities:
Net loss	$	(43,632)	$	(39,188)	$	(38,565)	$	(43,632)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		345		336		316		345
Stock-based compensation expense		6,966		1,984		7,503		6,966
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(1,563)		356		(3,259)		(1,563)
Accounts receivable		117		344		187		117
Accounts payable		(139)		(263)		(559)		(139)
Accrued expenses and other liabilities		1,279		3,966		(66)		1,279
Net cash used in operating activities		(36,627)		(32,465)		(34,443)		(36,627)
Cash flows from investing activities:
Purchases of property and equipment		(43)		(391)		(214)		(43)
Net cash used in investing activities		(43)		(391)		(214)		(43)
Cash flows from financing activities:
Payment of deferred issuance costs associated with Series B convertible preferred stock financing		—		(232)
Proceeds from initial public offering, net of underwriters' discounts		—		109,517
Proceeds from stock options exercised		282		2		490		282
Payment of deferred offering costs		(181)		(2,971)
Proceeds from public offering, net of underwriters' discounts						33,672		—
Proceeds from at the market offering, net of sales commission						5,799		—
Payment of offering costs						(417)		(181)
Net cash provided by financing activities		101		106,316		39,544		101
Net (decrease) increase in cash, cash equivalents and restricted cash		(36,569)		73,460
Net increase (decrease) in cash, cash equivalents and restricted cash						4,887		(36,569)
Cash, cash equivalents and restricted cash, at beginning of period		151,128		92,609		99,194		151,128
Cash, cash equivalents and restricted cash, at end of period	$	114,559	$	166,069	$	104,081	$	114,559
Supplemental disclosure of non-cash investing and financing activities:
Deferred offering costs not yet paid	$	17	$	41
Offering costs not yet paid					$	—	$	17

See accompanying notes to these unaudited condensed financial statements.

Table of Contents

Aptinyx Inc.

Condensed Statements of ~~Convertible Preferred Stock and~~ Stockholders’ ~~(Deficit)~~ Equity

(unaudited)

(in thousands)


	Series A‑1			Series A‑2			Series B										Total
	convertible			convertible			convertible						Additional				stockholders’
	preferred stock			preferred stock			preferred stock			Common stock			paid-in		Accumulated		equity
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		capital		deficit		(deficit)


																						Additional				Total
																			Common stock			paid-in		Accumulated		stockholders’
																			Shares	Amount		capital		deficit		equity
Balance at June 30, 2020																			46,850	$	468	$	307,015	$	(190,175)	$	117,308
Stock-based compensation																			—		—		2,669		—		2,669
Issuance of common stock upon at the market offering, net of sales commission and other offering costs of $37																			299		3		1,127		—		1,130
Issuance of common stock upon exercise of stock options																			8		—		17		—		17
Net loss																			—		—		—		(11,338)		(11,338)
Balance at September 30, 2020																			47,157	$	471	$	310,828	$	(201,513)	$	109,786

Balance at June 30, 2019	—	$	—	—	$	—	—	$	—	33,608	$	336	$	259,090	$	(134,380)	$	125,046	33,608	$	336	$	259,090	$	(134,380)	$	125,046
Issuance of common stock upon vesting of restricted stock	—		—	—		—	—		—	54		1		(1)		—		—	54		1		(1)				—
Stock-based compensation	—		—	—		—	—		—	—		—		2,641		—		2,641	—		—		2,641		—		2,641
Issuance of common stock upon exercise of stock options	—		—	—		—	—		—	14		—		30		—		30	14		—		30		—		30
Net loss	—		—	—		—	—		—	—		—		—		(14,790)		(14,790)	—		—		—		(14,790)		(14,790)
Balance at September 30, 2019	—	$	—	—	$	—	—	$	—	33,676	$	337	$	261,760	$	(149,170)	$	112,927	33,676	$	337	$	261,760	$	(149,170)	$	112,927

Balance at June 30, 2018	—	$	—	—	$	—	—	$	—	33,155	$	332	$	252,473	$	(77,264)	$	175,541


																						Additional				Total
																			Common stock			paid-in		Accumulated		stockholders’
																			Shares	Amount		capital		deficit		equity
Balance at December 31, 2019																			33,739	$	337	$	263,922	$	(162,948)	$	101,311
Issuance of common stock upon vesting of restricted stock	—		—	—		—	—		—	73		—		—		—		—	23		—		—		—		—
Stock-based compensation	—		—	—		—	—		—	—		—		720		—		720
Stock‑based compensation																			—		—		7,503		—		7,503
Issuance of common stock upon public offering, net of underwriters’ discount and other offering costs of $1,733																			11,692		117		33,225		—		33,342
Issuance of common stock upon at the market offering, net of sales commission and other offering costs of $274																			1,491		15		5,690		—		5,705
Issuance of common stock upon exercise of stock options										1		—		2		—		2	212		2		488		—		490
Issuance of common stock upon IPO, net of underwriters’ discount and other offering costs of $2,902	—		—	—		—	—		—	—		—		(111)		—		(111)
Net loss	—		—	—		—	—		—	—		—		—		(14,181)		(14,181)	—		—		—		(38,565)		(38,565)
Balance at September 30, 2018	—	$	—	—	$	—	—	$	—	33,229	$	332	$	253,084	$	(91,445)	$	161,971

	Series A‑1			Series A‑2			Series B										Total
	convertible			convertible			convertible						Additional				stockholders’
	preferred stock			preferred stock			preferred stock			Common stock			paid-in		Accumulated		equity
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		capital		deficit		(deficit)

Balance at September 30, 2020																			47,157	$	471	$	310,828	$	(201,513)	$	109,786

Balance at December 31, 2018	—	$	—	—	$	—	—	$	—	33,341	$	333	$	254,516	$	(105,538)	$	149,311	33,341	$	333	$	254,516	$	(105,538)	$	149,311
Issuance of common stock upon vesting of restricted stock	—		—	—		—	—		—	193		2		(2)		—		—	193		2		(2)		—		—
Stock‑based compensation	—		—	—		—	—		—	—		—		6,966		—		6,966	—		—		6,966		—		6,966
Issuance of common stock upon exercise of stock options	—		—	—		—	—		—	142		2		280		—		282	142		2		280		—		282
Net loss	—		—	—		—	—		—	—		—		—		(43,632)		(43,632)	—		—		—		(43,632)		(43,632)
Balance at September 30, 2019	—	$	—	—	$	—	—	$	—	33,676	$	337	$	261,760	$	(149,170)	$	112,927	33,676	$	337	$	261,760	$	(149,170)	$	112,927

Balance at December 31, 2017	151,773	$	22,650	173,453	$	39,979	234,955	$	69,757	5,342	$	53	$	12,486	$	(52,257)	$	(39,718)
Issuance of common stock upon vesting of restricted stock	—		—	—		—	—		—	220		2		(2)		—		—
Stock‑based compensation	—		—	—		—	—		—	—		—		1,984		—		1,984
Issuance of common stock upon exercise of stock options										1		—		2		—		2
Conversion of preferred stock upon IPO	(151,773)		(22,650)	(173,453)		(39,979)	(234,955)		(69,757)	20,306		203		132,183		—		132,386
Issuance of common stock upon IPO, net of underwriters’ discount and other offering costs of $2,902	—		—	—		—	—		—	7,360		74		106,431		—		106,505
Net loss	—		—	—		—	—		—	—		—		—		(39,188)		(39,188)
Balance at September 30, 2018	—	$	—	—	$	—	—	$	—	33,229	$	332	$	253,084	$	(91,445)	$	161,971

See accompanying notes to the unaudited condensed financial ~~statements~~statements.

Table of Contents

Aptinyx Inc.

Notes to Condensed Financial Statements

~~(Unaudited)~~(unaudited)

1. Organization

Description of business

Aptinyx Inc. (the “Company” or “Aptinyx”) was incorporated in Delaware on June 24, 2015 and maintains its headquarters in Evanston, Illinois.

Aptinyx is a ~~clinical‑stage~~clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovering proprietary compounds that work through a novel mechanism: modulation of ~~N‑methyl‑D‑aspartate~~N-methyl-D-aspartate receptors (“NMDAr”), which are vital to normal and effective brain and nervous system functions. This mechanism has applicability across numerous brain and nervous system disorders.

~~Initial~~Liquidity and capital resources

On January 14, 2020, the Company completed a follow-on public offering

~~On June 20, 2018, the Company’s~~ of its common stock pursuant to an effective registration statement on Form S‑~~1 (File No. 333‑225150) relating to the initial public offering (“IPO”)~~S-3. The Company sold an aggregate of ~~its common stock became effective and on June 25, 2018, the IPO closed. Pursuant to the IPO, the Company issued and sold 7,359,998~~11,691,666 shares of common stock, ~~at a public offering price of $16.00 per share,~~ which included ~~959,999 shares sold pursuant to~~ the exercise in full of the underwriters’ option to purchase additional ~~shares. The Company received net~~shares, at a public offering price of $3.00 per share. Net proceeds ~~of $106.5~~from the offering were approximately $33.3 million after deducting underwriting discounts and commissions ~~and~~as well as other offering costs of $3.0 million. The shares began trading on the Nasdaq Global Select Market on June 21, 2018. Upon the closing of the IPO, all of the Company’s outstanding shares of convertible preferred stock automatically converted into 20,306,497 shares of common stock at the applicable conversion ratio.expenses.

~~At the market offering program~~

On July 1, 2019, the Company entered into a Sales Agreement ~~(the “Sales Agreement”)~~ with Cowen and Company, LLC (“Cowen”), pursuant to which the Company may ~~issue~~offer and sell ~~from time to time,~~ shares of its common stock ~~having~~with an aggregate offering price of up to $50.0 million ~~through Cowen as sales agent. Cowen may sell common stock by any method permitted by law deemed to be~~under an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or through the Nasdaq Global Select Market or any other existing trade market for the common stock, in negotiated transactions at market prices prevailing at the time of sale or at prices related to prevailing market prices, or any other method permitted by law.market” offering program (the “ATM Offering”). The Sales Agreement provides that Cowen will be entitled to ~~receive~~a sales commission equal to 3.0% of the gross sales price per share of ~~common stock~~all shares sold under the ~~Sales Agreement. As~~ATM Offering. No sales from the ATM occurred in 2019. For the nine months ended September 30, 2020, the Company sold an aggregate of ~~the date~~1,491,482 shares at a weighted-average price of ~~these financial statements, no shares~~$3.89 per share for net proceeds of ~~common stock have been issued~~$5.7 million after deducting sales commission and ~~sold pursuant to the Sales Agreement.~~other offering expenses.

~~Liquidity and capital resources~~

As of September 30, ~~2019,~~2020, the Company had cash and cash equivalents of ~~$114.2~~$103.8 million, which the Company believes will be sufficient to funds its planned operations for a period of at least twelve months from the date of issuance of these condensed financial statements.

On October 26, 2020, the Company completed a ~~2.Summary~~follow-on public offering of its common stock pursuant to an effective registration statement on Form S-3. The Company sold an aggregate of 16,100,000 shares of common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share. Net proceeds from the offering were approximately $45.1 million after deducting underwriting discounts and commissions as well as estimated offering expenses.

2.Summary of significant accounting policies

Basis of presentation

The condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted from this report, as is permitted by such rules and

~~Table of Contents~~

regulations. The accompanying condensed financial statements reflect all adjustments consisting of normal, recurring adjustments that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of results for a full year. Accordingly, these

Table of Contents

condensed financial statements should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2018~~2019 (the “Annual Report”) filed with the SEC on March ~~21, 2019.~~ 30, 2020.

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company, and has elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.

~~Reverse stock split~~

On June 7, 2018, the Company effected a one-for‑27.58621 reverse stock split of the Company’s issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for the Company’s convertible preferred stock. The par value per share and authorized shares of common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock and common stock per share amounts within the financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.

Use of estimates

The condensed financial statements are prepared in conformity with GAAP. This process requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Risk and uncertainties

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of: the impact of COVID-19 on future clinical study results, the scope, timing, rate of progress, and expense of the Company’s ongoing as well as any additional preclinical studies, clinical studies, and other research and development activities, clinical study enrollment rate or design, the manufacturing of the Company’s product candidates, significant and changing government regulation, and the timing and receipt of any regulatory approvals.

A novel strain of coronavirus (COVID-19) was first identified in December 2019, and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the outbreak, many companies have experienced disruptions in their operations and in markets served. On March 27, 2020, the Company suspended patient enrollment for certain ongoing Phase 2 clinical studies, including its NYX-2925 studies in painful diabetic peripheral neuropathy and fibromyalgia and its NYX-483 study in Parkinson’s disease cognitive impairment. The Company began re-enrollment in its NYX-2925 study in fibromyalgia in September 2020. The Company has initiated some and may take additional temporary precautionary measures intended to help ensure the well-being of its employees and minimize business disruption. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company’s results of operations and financial position at September 30, 2020. The full extent of the future impacts of COVID-19 on the Company’s operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the availability of capital, timing and ability of the Company to complete certain clinical studies, and other efforts required to advance the development of its targets.

Significant accounting policies

The Company’s significant accounting policies are described in Note 3, “Summary of significant accounting policies,” in the Annual Report. There have been no material changes to the significant accounting policies during the nine months ended September 30, ~~2019 with the exception of the following:~~2020.

~~Revenue Recognition~~

Revenue is recognized in accordance with revenue recognition accounting guidance, which utilizes five steps to determine whether revenue can be recognized and to what extent: (i) identify the contract with a customer; (ii) identify the performance obligation(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) determine the recognition period. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, ~~Revenue from Contracts with Customers,~~ the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Significant judgments exercised by management include the identification of performance obligations, and whether such promised goods or services are considered distinct. The Company evaluates promised goods or services on a contract by contract basis to determine whether each promise represents a good or service that is distinct or has the same pattern of

~~Table of Contents~~

transfer as other promises. A promised good or service is considered distinct if the customer can benefit from the good or service independently of other goods/services either in the contract or that can be obtained elsewhere, without regard to contract exclusivity, and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contact. If the good or service is not considered distinct, the Company combines such promises and accounts for them as a single combined performance obligation.

~~Recently adopted accounting pronouncements~~

In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in ASC Topic 605, ~~Revenue Recognition, (“ASC 605”), and creates a new topic, ASC 606,~~ ~~Revenue from Contracts with Customers~~. Through subsequent targeted amendments, the FASB issued additional ASUs that delayed the effective date of ASC 606 and clarified various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations, licensing, and other improvements and practical expedients. The Company adopted this new standard on January 1, 2019 using the modified retrospective transition method. The Company presents revenue from contracts with customers as collaboration revenue in the Company’s condensed statements of operations. The Company applied this new standard to all contracts with customers that were not complete as of the adoption date and has determined that no cumulative catch-up adjustment to accumulated deficit was required. See Note 4, “Research collaboration agreement with Allergan” for additional information regarding the Company’s single contract that falls within the scope of ASC 606.

The Company has determined that the accounting for the Company’s various grant agreements is outside the scope of ASC 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. There are currently no grants outstanding in 2019. Since the accounting for government grants falls outside the scope of ASC 606, the Company has classified the grant income earned in 2018 separate and apart from revenue earned from contracts with customers in the Company’s condensed statements of operations.

~~In June 2018, the FASB issued ASU 2018-07,~~ ~~Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU expands the scope of Topic 718,~~ ~~Compensation—Stock Compensation~~ to include share-based payments issued to nonemployees for goods or services. Under the new guidance, the existing employee guidance will apply to nonemployee share based transactions (as long as the transaction is not effectively a form of financing), with the exception of specific guidance related to the attribution of compensation cost. The cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods or services. The new accounting guidance will be effective for the Company on January 1, 2020. The Company has early adopted this new standard on January 1, 2019. The adoption did not have a material impact on the Company’s condensed financial statements.

Recently issued accounting pronouncement

In February 2016, the FASB issued ASU No. ~~2016‑02,~~ 2016-02, Leases (“ASU ~~2016‑02”~~2016-02”), as amended, which requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. The new standard includes a ~~short‑term~~short-term lease exception for leases with a term of 12 months or less, as part of which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities.

Table of Contents

Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases using classification criteria that are substantially similar to the previous guidance. The new standard will be effective for the Company for annual reporting periods beginning after December 15, ~~2019,~~2021 and interim periods within fiscal years beginning after December 15, 2022, and early adoption is permitted. The Company anticipates that the adoption of this standard will have an impact on its balance sheet due to the recognition of right-of-use assets and lease liabilities; however, the Company is currently evaluating the ~~potential~~ impact that the adoption of ASU ~~2016‑02~~2016-02 may have on its condensed financial statements.

3. Supplemental financial information

Cash, cash equivalents and restricted cash

Cash and cash equivalents consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased. The following table provides a reconciliation of cash, cash equivalents, and

~~Table of Contents~~

restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (amounts in thousands).


	As of		As of
	September 30,		December 31,
	2019		2018

					As of		As of
					September 30,		December 31,
					2020		2019
Cash and cash equivalents	$	114,214	$	150,637	$	103,810	$	98,849
Short-term and long-term restricted cash		345		491		271		345
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$	114,559	$	151,128	$	104,081	$	99,194

Prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following (in thousands):


	As of		As of
	September 30,		December 31,
	2019		2018

					As of		As of
					September 30,		December 31,
					2020		2019
Prepaid clinical	$	1,970	$	728	$	6,465	$	3,719
Prepaid insurance		1,220		673		1,470		994
Prepaid manufacturing costs		435		—		558		558
Other prepaid expenses and current assets		355		383		343		366
Total prepaid expenses and other current assets	$	3,980	$	1,784	$	8,836	$	5,637

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):


	As of		As of
	September 30,		December 31,
	2019		2018

					As of		As of
					September 30,		December 31,
					2020		2019
Employee-related expenses	$	1,954	$	2,043	$	1,483	$	1,925
Development costs and sponsored research		1,746		915		843		652
Clinical trials		1,176		607		190		410
Professional services		125		211		328		206
Other		343		220		437		148
Total accrued expenses and other current liabilities	$	5,344	$	3,996	$	3,281	$	3,341

Table of Contents

4. Research collaboration agreement with Allergan

On July 24, 2015, the Company entered into a Research Collaboration Agreement (“RCA”) with Naurex Inc., a subsidiary of Allergan plc (“Allergan”), which became a wholly owned subsidiary of AbbVie Inc. in May 2020. The RCA is focused on the research and discovery of small molecules that modulate NMDArs. The collaboration is supervised by a Joint Steering Committee (“JSC”) comprising an equal number of representatives from both the Company and Allergan. Under the terms of the agreement, the RCA will terminate upon the earlier of (i) 180 days after a predetermined anniversary of the effective date of the RCA ~~or on~~and (ii) the date on which Allergan exercises the last of three options to acquire molecules from a pool of eligible ~~compounds.~~compounds in both cases (clauses (i) and (ii)) subject to potential extension if and as required for the Company to transfer to Allergan information and technology related to compounds that were licensed by Allergan. The jointly funded research activities under the RCA and the associated payments by Allergan to the Company came to their contractual conclusion in accordance with the agreement in the third quarter of 2020. Under the terms of the agreement, Allergan will pay the Company $1.0 million for each option exercised by Allergan. On May 16, 2018, Allergan exercised its option to acquire exclusive rights to develop and commercialize AGN-241751 within a predefined set of indications.

The Company concluded that Allergan meets the definition of a customer, and therefore concluded that the RCA represents a contract with a customer that falls within the scope of ASC 606.

~~Table of Contents~~

Performance obligations

The Company identified the following promised goods or services within the RCA:

●

Research Licenses – the Company provides access to exclusive licenses under all of the Company’s NMDAr technologies, during the research term for the sole purpose of conducting research and development ~~activities.~~activities (the “Research Licenses”). Historically, the Company’s licenses have held no value to the customer on a standalone basis, as the research compounds were in the early discovery phase and required the Company’s expertise for further development. Accordingly, the Research Licenses are not considered distinct.

●

Research and Development Services – the Company provides research and development services that are performed on behalf of, or with, ~~Allergan.~~Allergan (the “Research and Development Services”). As discussed within Research Licenses above, the Company’s licenses have historically held no value without the specialized ~~research~~Research and ~~development services.~~Development Services. As the Company generally only provides ~~research~~Research and ~~development services~~Development Services for internally generated small molecules that modulate NMDArs which require a license to be utilized by a third party, the Research and Development Services are not considered distinct.

●

Joint Steering Committee – the Company actively participates in a joint steering committee, which allows the Company and its collaboration partner to direct the progression and prioritization of the joint discovery programs. As the ~~steering committee~~JSC would not occur or benefit the customer without the use of the Research Licenses and the related Research and Development Services, and given the Company’s proprietary knowledge of the Research Licenses and the NMDAr technologies, this is not considered distinct.

The Company also evaluated whether the option granted to the customer to acquire additional goods or services represented a material right at contract inception. Upon Allergan’s exercise of one of its options, the Company is obligated to transfer control of all intellectual property relating to the optioned compound to Allergan, after which the Company has no further interest in, or continuing involvement with, such optioned compound. The Company evaluated the customer options for material rights, that is, whether the option was to acquire additional goods or services for free or at a discount, and concluded that the options are priced, at contract inception, at standalone selling price. Consequently, the customer options do not represent a performance obligation at the outset of the arrangement since they are contingent upon the option exercise which is outside of the Company’s control.

The Company has concluded that there is a single combined performance obligation (comprising the Research Licenses, Research and Development Services, and participation onin the ~~Joint Steering Committee)~~JSC) which is satisfied over time, as the ~~research~~Research and ~~development services~~Development Services are performed. The exercise of the option to acquire exclusive rights to develop and commercialize AGN-241751 or any future options exercised are not considered a performance obligation until the time of option exercise.

Table of Contents

Transaction ~~Price~~price

The RCA includes both fixed and variable consideration. Fixed payments, such as contractually defined fees per full-time employee (“FTE”), are included in the transaction price at contract inception, while variable consideration, such as reimbursement for Research and Development Services, are estimated and then evaluated for constraints upon inception of the contract and evaluated on a quarterly basis thereafter. Research and Development Services are updated for actual invoices. There were no capitalized costs associated with obtaining the contract.

The Company concluded that it will use an input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. The Company uses fixed FTE efforts and variable out-of-pocket costs as actual costs incurred relative to the annual budget research plan to measure progress towards fulfillment of the performance obligation. An input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. The Company does not anticipate significant changes as the research plan is reviewed and adjusted annually and approved by the JSC. There are no significant financing components in the contract.

~~Table of Contents~~

The Company has determined that the option fee is representative of standalone selling price and concluded that it will recognize revenue for the option fee at a point in time, on the date of exercise, due to the significant uncertainty of whether or not Allergan would exercise the option. The Company recognizes the option fee at a point in time because control of the underlying intellectual property transfers to the customer, and the customer is able to use and benefit from the license. The Company has no further rights, interests, or remaining performance obligations associated with any optioned compound, once exercised.

During ~~each of~~ the three months ended September 30, ~~2019~~2020 and ~~2018,~~2019, the Company recorded expenses of $1.9 million for certain development activities in accordance with the terms of the RCA, of which 50% was reimbursed by Allergan. The Company received reimbursements of $0.9 million during each of the three months ended September 30, 2019 and 2018. During the nine months ended September 30, 2019 and 2018, the Company recorded expenses of $5.5$0.6 million and ~~$5.8~~$1.9 million, respectively, for certain development activities in accordance with the terms of the RCA, of which 50% was reimbursed by Allergan. The Company received reimbursements of ~~$2.8~~$0.3 million and ~~$2.9~~$0.9 million during the three months ended September 30, 2020 and 2019, respectively. During the nine months ended September 30, 2020 and 2019, the Company recorded expenses of $3.1 million and $5.5 million, respectively, for certain development activities in accordance with the terms of the RCA, of which 50% was reimbursed by Allergan. The Company received reimbursements of $1.6 million and $2.8 million during the nine months ended September 30, ~~2019~~2020 and ~~2018,~~2019, respectively. Such reimbursements were reported within ~~collaboration~~ revenue in the condensed statements of operations. All of the Company’s accounts ~~receivables~~receivable as of both September 30, ~~2019~~2020 and December 31, ~~2018~~2019 relate to amounts owed by Allergan under the RCA.On May 16, 2018, Allergan exercised its option to acquire exclusive rights to develop and commercialize AGN-241751 within a specific set of indications. For the three and nine months ended September 30, 2018, the Company recognized the $1.0 million non-refundable milestone payment within collaboration revenue in the condensed statements of operations as there were no remaining performance obligations associated with the optioned compound.

5. Fair value measurements

ASC 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:

●

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;

●

Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

●

Level 3 inputs are unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

Table of Contents

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The carrying values reported in the Company’s balance sheets for cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued expenses are reasonable estimates of their fair values due to the short-term nature of these items.

~~Table of Contents~~

Assets measured at fair value as of September 30, ~~2019~~2020 are as follows (in thousands):






	September 30,
	2019		Level 1		Level 2		Level 3





									September 30,
									2020		Level 1		Level 2		Level 3
Assets
Money market funds, included in cash and cash equivalents	$	114,059	$	114,059	$	—	$	—	$	102,710	$	102,710	$	—	$	—
Money market funds, included in restricted cash		179		179		—		—		179		179		—		—
Money market funds, included in other assets		166		166		—		—		92		92		—		—
	$	114,404	$	114,404	$	—	$	—
									$	102,981	$	102,981	$	—	$	—

Assets measured at fair value as of December 31, ~~2018~~2019 are as follows (in thousands):






	December 31,
	2018		Level 1		Level 2		Level 3





									December 31,
									2019		Level 1		Level 2		Level 3
Assets
Money market funds, included in cash and cash equivalents	$	150,151	$	150,151	$	—	$	—	$	97,998	$	97,998	$	—	$	—
Money market funds, included in restricted cash		252		252		—		—		179		179		—		—
Money market funds, included in other assets		239		239		—		—		166		166		—		—
	$	150,642	$	150,642	$	—	$	—
									$	98,343	$	98,343	$	—	$	—

6. Property and equipment, net

Property and equipment are as follows (in thousands):


	As of		As of
	September 30,		December 31,
	2019		2018

					As of		As of
					September 30,		December 31,
					2020		2019
Computer software and equipment	$	15	$	15	$	15	$	15
Office equipment and furniture		176		176		176		176
Laboratory equipment		1,614		1,571		1,801		1,597
Leasehold improvements		1,051		1,051		1,062		1,051
Construction-in-progress						—		11
Less accumulated depreciation		(1,526)		(1,123)		(2,021)		(1,646)
Property and equipment, net	$	1,330	$	1,690	$	1,033	$	1,204

Depreciation expense was $0.1 million for each of the three months ended September 30, 2020 and 2019, ~~and 2018,~~respectively, and $0.4 million for each of the nine months ended September 30, 2020 and 2019, ~~and 2018.~~respectively.

Table of Contents

7. Stock incentive plans

On June 5, 2018, the Company’s stockholders approved the 2018 Stock Option and Incentive Plan (the “2018 Plan”), which became effective on June 20, 2018. The 2018 Plan provides for an annual increase, to be added on the first day of each fiscal year, of up to 4% of the Company’s outstanding shares of common stock as of the last day of the prior year. On January 1, ~~2019, 1,341,436~~2020, 1,349,165 shares of common stock were added to the 2018 Plan. The number of shares available for grant under the Company’s 2018 Plan as of September 30, ~~2019~~2020 was 2,809,289 which includes 505,046 shares of the Company’s common stock reserved under the Company’s 2015 Stock Option and Grant Plan (the “2015 Plan”) that became available for issuance upon the effectiveness of the 2018 Plan. No future issuance will be made under the 2015 Plan.2,226,327.

~~Table of Contents~~

~~Stock‑based~~Stock-based compensation expense

Non-cash stock-based compensation expense recognized in the accompanying condensed statements of operations relating to ~~both~~ stock options, restricted stock awards, and restricted stock units for the three and nine months ended September 30, ~~2019~~2020 and ~~2018~~2019 was as follows (in thousands):


	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018

									Three months ended				Nine months ended
									September 30,				September 30,
									2020		2019		2020		2019
Research and development	$	816	$	242	$	2,181	$	616	$	645	$	816	$	1,660	$	2,181
General and administrative		1,825		478		4,785		1,368		2,024		1,825		5,843		4,785
Total stock‑based compensation expense	$	2,641	$	720	$	6,966	$	1,984	$	2,669	$	2,641	$	7,503	$	6,966

Stock options

The table below summarizes activity related to stock options (in thousands, except per share amounts):


				Weighted‑
		Weighted‑		average
		average		remaining	Aggregate
		exercise		contractual	intrinsic

										Weighted‑
								Weighted‑		average
								average		remaining	Aggregate
								exercise		contractual	intrinsic
Options	Shares	price		term	value		Shares	price		term	value
Outstanding, December 31, 2018	3,959	$	7.46	8.79	$	35,984
Outstanding, December 31, 2019							4,798	$	8.75	8.29	$	1,159
Granted	1,663		12.77				2,405		3.12
Exercised	(142)		1.99				(212)		2.32
Forfeited and canceled	(522)		11.91				(326)		8.96
Outstanding, September 30, 2019	4,958	$	8.93	8.45	$	1,356
Vested and expected to vest at September 30, 2019	4,958	$	8.93	8.45	$	1,356
Exercisable at September 30, 2019	1,877	$	5.37	7.90	$	968
Outstanding, September 30, 2020							6,665	$	6.91	8.25	$	1,547
Vested and expected to vest at September 30, 2020							6,665	$	6.91	8.25	$	1,547
Exercisable at September 30, 2020							3,022	$	7.15	7.55	$	826

During the nine months ended September 30, ~~2019~~2020 and ~~2018,~~2019, the Company granted ~~1.7~~2.4 million and ~~2.4~~1.7 million stock options, respectively and these options had a weighted-average grant-date fair value of ~~$8.36~~$2.06 and ~~$9.95~~$8.36 per share, respectively. The weighted-average grant-date fair value of options was determined using the Black-Scholes option-pricing model. The assumptions used in the Black-Scholes option-pricing model for options granted during the ~~three and~~ nine months ended September 30, ~~2019~~2020 were similar to those as described in the Annual Report. As of September 30, ~~2019,~~2020, there was ~~$20.4~~$15.3 million of total unrecognized stock-based compensation expense related to non-vested stock options which is expected to be recognized over a weighted-average period of ~~2.90~~2.3 years. The options have a ten-year life and generally vest over a period of four years, subject to continuous employment.

Restricted stock awards

During the nine months ended September 30, 2020, the Company issued 6,392 restricted stock awards to a board member that vested immediately on the date of grant. Non-cash restricted stock award expense recognized in the accompanying condensed statements of operations was less than $0.1 million for ~~each of the three months ended September 30, 2019 and 2018 and~~ ~~$0.3 million for each of~~ the nine months ended September 30, ~~2019~~2020 and ~~2018.~~$0.3 million for the nine months ended September 30, 2019. The total fair value of the shares that vested was less than $0.1 million in the nine months ended September 30, ~~2019 was~~2020 and $0.2 ~~million.~~million in the nine months ended September 30, 2019. At September 30, ~~2019,~~2020, there ~~was less than $0.1 million of unrecognized compensation cost related to 3,632~~are no unvested restricted stock ~~awards that will be recognized as expense over a weighted-average period~~awards.

Table of ~~less than 0.01 years.~~Contents

Restrictedstock units

In June 2020 and May 2019, the Company issued an aggregate of 205,200 and 1,183,400 ~~shares of~~ restricted stock units, respectively, to employees. The restricted stock units issued in 2020 vest ten months from the date of grant. The restricted stock units issued in 2019 vest two years from the date of grant. The Company at any time may accelerate the vesting of the restricted stock units. Such shares are not accounted for as outstanding until they vest. ~~There are 2,166 shares of common stock underlying restricted stock units outstanding as of September 30, 2019.~~

~~Table of Contents~~

The table below summarizes activity related to restricted stock units (in thousands, except per share amounts):


		Weighted‑
		average
		grant date
		fair value
	Shares	per share
Unvested as of December 31, 2018	-	$	-

					Weighted‑
					average
					grant date
					fair value
				Shares	per share
Unvested as of December 31, 2019				1,032	$	3.63
Issued	1,183	$	3.63	205	$	3.61
Vested	(2)		3.63	(21)		3.63
Forfeited and canceled	(26)		3.63	(88)		3.63
Unvested as of September 30, 2019	1,155	$	3.63
Unvested as of September 30, 2020				1,128	$	3.63

Non-cash restricted stock unit award expense recognized in the accompanying condensed statements of operations was $0.6 million for each of the three months ended September 30, 2020 and 2019, respectively, and $1.5 million and $0.8 million for the ~~three and~~ nine months ended September 30, 2020 and 2019, respectively. At September 30, ~~2019,~~2020, there was ~~$3.4~~$1.5 million of unrecognized stock-based compensation related to ~~1,154,934~~1,128,300 unvested restricted stock units that will be recognized as expense over a weighted-average period of ~~1.63~~0.6 years.

8. Net loss per share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows for the three and nine months ended September 30, ~~2019~~2020 and ~~2018~~2019 (in thousands, except per share data):


	Three months ended				Nine months ended
	September 30,				September 30,
	2019		2018		2019		2018

									Three months ended				Nine months ended
									September 30,				September 30,
									2020		2019		2020		2019
Numerator:
Net loss attributable to common stockholders	$	(14,790)	$	(14,181)	$	(43,632)	$	(39,188)	$	(11,338)	$	(14,790)	$	(38,565)	$	(43,632)
Denominator:
Weighted-average common shares outstanding—basic and diluted		33,646		33,191		33,510		15,789		46,978		33,646		45,503		33,510
Net loss per share attributable to common stockholders—basic and diluted	$	(0.44)	$	(0.43)	$	(1.30)	$	(2.48)	$	(0.24)	$	(0.44)	$	(0.85)	$	(1.30)

The following common stock equivalents outstanding as of September 30, ~~2019~~2020 and ~~2018,~~2019, were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been ~~anti‑dilutive~~anti-dilutive (in thousands):


	As of
	September 30,
	2019	2018

			As of
			September 30,
			2020	2019
Stock options issued and outstanding	4,958	3,937	6,665	4,958
Unvested restricted stock	1,159	268	1,128	1,159
Total	6,117	4,205	7,793	6,117

Table of Contents

9. Income taxes

Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, including its net operating losses. Based on its history of operating losses, the Company believes that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of September 30, ~~2019~~2020 and December 31, ~~2018.~~2019.

~~Table~~On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in the United States. The CARES Act, among other things, permits net operating loss (“NOL”) carryovers and carrybacks to offset 100% of ~~Contents~~

taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.

10. Commitments and contingencies

Contingencies

From time to time, the Company may be subject to occasional lawsuits, investigations, and claims arising out of the normal conduct of business. The Company has no significant pending or threatened litigation as of September 30, ~~2019.~~2020.

Indemnifications

In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company’s request in such capacities. The Company’s maximum exposure under these arrangements is unknown at September 30, ~~2019.~~2020. The Company does not anticipate recognizing any significant losses relating to these arrangements.

Leases

The Company enters into various non-cancelable, operating lease agreements for its facilities and equipment in order to conduct its operations. The Company expenses rent on a straight-line basis over the life of the lease and has recorded deferred rent on the Company’s balance sheets within both accrued expenses and other current liabilities and other long-term liabilities.

Total rent expense, inclusive of lease incentives, under all the operating lease agreements amounted to $0.3 million and $0.2 million for ~~each of~~ the three months ended September 30, 2020 and 2019, respectively, and ~~2018~~$0.7 million and $0.6 ~~million and~~ ~~$0.5~~ million for the nine months ended September 30, 2020 and 2019, respectively.

11.Subsequent Events

On October 26, 2020, the Company completed a follow-on public offering of its common stock pursuant to an effective registration statement on Form S-3. The Company sold an aggregate of 16,100,000 shares of common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share. Net proceeds from the offering were approximately $45.1 million after deducting underwriting discounts and ~~2018, respectively.~~commissions as well as estimated offering expenses.

1817

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion should be read in conjunction with our condensed financial statements and accompanying footnotes appearing elsewhere in this Quarterly Report on Form ~~10‑Q~~10-Q and our audited financial statements and related footnotes included in our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, or Annual Report, filed with the Securities and Exchange Commission, or the SEC, on March ~~21, 2019.~~ 30, 2020.

Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form ~~10‑Q,~~10-Q, including information with respect to our plans and strategy for our business, ~~and related financing,~~ includes forward-looking statements that involve risks and uncertainties. See “Special Note Regarding Forward-Looking Statements.” Because of many factors, including those factors set forth in the “Risk Factors” section of our Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Overview

We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. ~~We focus our efforts on targeting~~Our compounds target and ~~modulating~~modulate N-methyl-D-aspartate receptors, or NMDArs, which are vital to normal and effective function of the brain and nervous system. We believe leveraging the therapeutic advantages of the differentiated modulatory mechanism of our compounds will drive a paradigm shift in the treatment of disorders of the brain and nervous system.

We are advancing a pipeline of distinct product candidates derived from our NMDAr modulator discovery platform, or the discovery platform. ~~We currently~~To date, we have advanced three ~~wholly owned, clinical-stage~~ product candidates from our NMDAr modulator discovery platform into human clinical studies in ~~development for various central nervous system,~~the areas of post-traumatic stress disorder, or ~~CNS, disorders. Each~~PTSD, chronic pain, and cognitive impairment. The table below depicts the current Phase of development of our ~~development-stage assets has unique pharmacological properties, including with regard to binding,~~pipeline of clinical-stage novel NMDAr ~~subtype selectivity, potency, and activity in preclinical behavioral models. These unique properties inform the identification of the indication(s) for which each product candidate is developed.~~modulators.

~~Our product candidate,~~

NYX-2925 is ~~a novel, oral small-molecule NMDAr modulator that has demonstrated effects on biomarkers of pain processing as well as alleviation of pain and other symptoms in clinical studies. NYX-2925 is currently~~ in Phase 2 clinical development ~~as a~~for the treatment ~~for~~of chronic pain. ~~In June 2019, we reported positive results from a 23-patient, sequential design, Phase 2 neuroimaging biomarker study in which~~ NYX-2925 ~~was shown to have statistically significant effects on pain-processing biomarkers and patient-reported measures of pain and other fibromyalgia symptoms. NYX-2925 has also been~~is being evaluated in atwo Phase ~~2 study~~2b studies in two chronic pain conditions: one evaluating the efficacy and safety in approximately 200 patients with painful diabetic peripheral neuropathy, or DPN. In the total study population (N=300), the primary endpoint was not met; however, a post-hoc sub-group analysis revealed robust analgesic activity in a large subset of patients—patients with advanced DPN (i.e.  4 years since DPN diagnosis, N=127)—in which the preponderance of patients' pain is most likely to be centrally mediated and addressed by the central mechanism of NYX-2925. Together, the effects on neuroimaging biomarkers and the robust analgesic effects observed in these two studies strongly support the continued development of NYX-2925 for centralized chronic pain conditions. In a Phase 1 single- and multiple-ascending dose study, NYX-2925 demonstrated a predictable and dose-dependent pharmacokinetic profile, achieving CNS exposure levels in line with brain exposure shown with preclinically efficacious doses. Additionally, NYX-2925 has demonstrated effects on NMDA receptor-dependent pathways across two Phase 1 EEG studies in healthy volunteers. Across all clinical studies conducted with NYX-2925 to date, it has been safe and well tolerated with no drug-related serious adverse events reported.

~~In follow up to the previous Phase 2 studies, we recently initiated two additional Phase 2 studies of NYX-2925 across two chronic pain conditions,~~ painful DPN, and ~~fibromyalgia. The Phase 2 study~~the other evaluating the efficacy and safety in approximately 300 patients with ~~painful DPN is a randomized, double-blind, placebo-controlled, study designed~~fibromyalgia. Due to ~~assess the safety~~challenges to patient recruitment, screening, and efficacy of NYX-2925. The study will recruit patients with advanced DPN – patients with a longer disease duration. The study will enroll approximately 200 patients who will be randomized to receive daily oral doses of 50 mg NYX-2925 or placebo. The primary endpoint in the study is the change from baseline on average daily pain scores over a 12-week period as reported on the 10-point numeric rating scale, or NRS. The Company expects to report top-line data from this study in late 2020 or early 2021.

randomization

1918

Table of Contents

~~The~~introduced by the COVID-19 pandemic, on March 27, 2020, we temporarily suspended enrollment of new patients in these studies. Patients already enrolled were allowed to continue as per the protocol. On September 28, 2020, we announced that we have re-activated study sites and recommenced patient recruitment in our Phase 2 study of NYX-2925 in patients with fibromyalgia is a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of NYX-2925. The study will enroll approximately 300 patients who will be randomized to receive 50 mg NYX-2925, 100 mg NYX-2925, or placebo. The primary endpoint of the study is the change from baseline on average daily pain scores over a 12-week period as reported on the 10-point NRS. The Company expects to reportfibromyalgia. We anticipate reporting top-line data from this study in the first half of ~~2021.~~

~~The~~2022. We also expect to recommence our Phase 2 study of NYX-2925 in patients with fibromyalgia is a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of NYX-2925. The study will enroll approximately 300 patients and will include a 14-week treatment period during which patients will receive 50 mg NYX-2925, 100 mg NYX-2925, or placebo. The primary endpoint of the study will be the change from baseline on average daily pain scores as reported on the 10-point NRS. The Company expects to report top-line data from this studypainful DPN in the ~~first half~~fourth quarter of ~~2021.~~2020.

~~Our product candidate,~~ NYX-783 is ~~a novel, oral, small-molecule NMDAr modulator currently~~ in Phase 2 clinical development for the treatment of ~~post-traumatic stress disorder, or~~PTSD. In October 2020, we announced positive results from the first Phase 2 study in 153 patients with PTSD. In the Phase 2 study, NYX-783 demonstrated clinically meaningful and statistically significant effects on numerous endpoints used to measure symptoms of PTSD. NYX-783 ~~has demonstrated robust activity in preclinical models of psychiatric disorders as well as models of fear conditioning~~also exhibited a favorable adverse event and ~~extinction learning.~~tolerability profile. Based on these ~~preclinical data and its mechanism of action, we believe NYX-783 has~~results, the ~~potential~~company expects to ~~address the underlying learning and memory dysfunction that underpins PTSD. In~~initiate a Phase 1 study conducted in healthy volunteers, NYX-783 was shown to be safe and well tolerated with no related serious adverse events. In the same Phase 1 study, NYX-783 demonstrated a predictable, dose-dependent, linear pharmacokinetic profile, and also achieved CNS exposure levels in line with brain exposure shown with preclinically efficacious doses. We are currently evaluating NYX-783 in a Phase 2 clinicalsubsequent study in ~~approximately 150 patients suffering from PTSD to assess its safety and efficacy. We expect to report data from this study in~~2021, designed such that it could be registration-supportive if the ~~second half of 2020.~~results are positive.

~~Our product candidate,~~ NYX-458 is ~~a novel, oral, small-molecule NMDAr modulator~~ in Phase 2 clinical development for the treatment of mild cognitive impairment associated with Parkinson’s disease. NYX-458 has exhibited marked effects on cognitive performance across a number of preclinical models. In studies conducted in non-human primates, NYX-458 has been shown to improve cognitive deficits akin to those seen in patients with Parkinson’s disease. In the studies, NYX-458 demonstrated rapid, robust, and long-lasting effects on attention, working memory, and cognitive flexibility, did not have any negative effects on motor symptoms, and did not interfere with the anti-parkinsonian effects of levodopa, the standard of care for treating the motor symptoms of Parkinson’s disease. In a Phase 1 study in healthy human volunteers NYX-458 was shown to be safe and well tolerated with no related serious adverse events. NYX-458 demonstrated a linear and predictable pharmacokinetic profile and was found to readily achieve CNS concentrations in line with concentrations of preclinically efficacious dose levels. In the fourth quarter of 2019, we expect to initiate aWe initiated an initial exploratory Phase 2 study of NYX-458 in patients with mild cognitive impairment associated with Parkinson’s disease ~~mild cognitive impairment.~~in December 2019. Due to challenges to patient recruitment, screening, and randomization introduced by the COVID-19 pandemic, on March 27, 2020, we suspended enrollment of new patients in this study. Patients already enrolled in this study were permitted to continue as per the protocol.

The continued spread of the COVID-19 pandemic has already and could further adversely impact our clinical and/or preclinical studies. In addition, COVID-19 has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions, and business shutdowns. COVID-19 has also caused volatility in the global financial markets and threatened a slowdown in the global economy, which may negatively affect our ability to raise additional capital on attractive terms or at all. See “Risk Factors—Risks related to our business, financial position, and need for additional capital—COVID-19 may materially and adversely affect our business and our financial results” in our Annual Report. The extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the severity of COVID-19 and the effectiveness of actions to contain and treat COVID-19. We cannot presently predict the scope and severity of any potential business shutdowns or disruptions, including to our ongoing and planned clinical studies. Any such shutdowns or other business interruptions could result in material and negative effects to our ability to conduct our business in the manner and on the timelines presently planned, which could have a material adverse impact on our business, results of operation, and financial condition.

Since our inception in June 2015, we have never generated revenue from the sale of our products and have incurred significant net losses. Our nominal revenues have been primarily derived from a research collaboration agreement with Allergan plc, or Allergan, a development services agreement with Allergan, and research and development grants from the U.S. government. While these revenues offset a small portion of the costs associated with our early stage research and discovery efforts, we do not rely on these revenues to fund our operations. In connection with the natural conclusion of our research collaboration with Allergan in the third quarter of 2020, we do not expect to continue to receive revenues from this collaboration.

From our inception through September 30, ~~2019,~~2020, we have raised an aggregate of $135 million of gross proceeds from sales of our convertible preferred stock, ~~and~~ $117.8 million of gross proceeds from our initial public offering, or ~~IPO.~~ IPO and $41.1 million of gross proceeds from our January 2020 follow-on public offering and our “at the market” offering program, or the ATM Offering. See “Liquidity and capital resources.” Our net losses were ~~$53.3~~$57.4 million and ~~$32.1~~$53.3 million for the years ended December 31, ~~2018~~2019 and ~~2017,~~2018, respectively, and ~~$43.6~~$38.6 million and ~~$39.2~~$43.6 million for the nine months ended September 30, ~~2019~~2020 and ~~2018,~~2019, respectively. As of September 30, ~~2019,~~2020, we had an accumulated deficit of ~~$149.2~~$201.5 million. Our net losses may fluctuate significantly from quarter to quarter and year to year. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will continue to increase in connection with our ongoing activities.

We believe that our available funds will be sufficient to fund our operations for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We do not expect to generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate, which we expect will

Table of Contents

take a number of years and the outcome of which is uncertain, or enter into collaborative agreements with third parties, the timing of which is largely beyond our control and may never occur. To fund our current and future operating plans, we ~~may~~will need additional capital, which we

~~Table of Contents~~

may obtain through one or more equity offerings, debt financings, or other third-party funding, including potential strategic alliances and licensing or collaboration arrangements. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at ~~all.~~all, including as a result of COVID-19. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our current product candidates, or any additional product candidates, if developed. The amount and timing of our future funding requirements will depend on many factors, including the impacts of COVID-19, our ability to timely and successfully enroll subjects in our clinical studies, and the pace and results of our preclinical and clinical development efforts. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.

Financial operations overview

Revenues

We have not generated any revenue from product sales. We are unable to predict when, if ever, material net cash inflows will commence from sales of our products, if approved. Our revenue to date has been primarily derived from a research collaboration agreement with ~~Allergan;~~Allergan, under which the jointly funded research activities and associated payments by Allergan to us concluded in the third quarter of 2020; a development services agreement with Allergan, which was put in place to continue certain development activities for a pre-determined period of time following Allergan's acquisition of Naurex Inc.; and research and development grants from the U.S. government ~~which~~that have no repayment or royalty ~~obligations.~~obligations and none of which are currently outstanding.

Operating expenses

Research and development expenses

Research and development activities account for a significant portion of our operating expenses. We expense research and development costs as incurred. Research and development expenses consist of costs incurred in connection with the development of our product candidates, including:

●

fees paid to consultants, sponsored researchers, contract manufacturing organizations, or CMOs, and contract research organizations, or CROs, including in connection with our preclinical and clinical studies, and other related clinical study fees, such as for investigator grants, patient screening, laboratory work, clinical study database management, and statistical compilation and analysis;

●

costs related to acquiring and maintaining preclinical and clinical study materials and facilities;

●

costs related to compliance with regulatory requirements; and

●

costs related to salaries, bonuses, and other compensation for employees in research and development functions.

At this time, we cannot reasonably estimate or know the nature, timing, and costs of the efforts that will be necessary to complete the development of our product candidates. This is due to the numerous risks and uncertainties associated with developing such product candidates, including the uncertainty related to:

●

the impacts of COVID-19;

●

future clinical study results; the scope, rate of progress, and expense of our ongoing as well as any additional preclinical studies, clinical studies and other research and development activities;

●

clinical study enrollment ~~rate;~~

rate or design;

●

~~clinical study design;~~

the manufacturing of our product candidates;

●

our ability to obtain ~~maintain, defend~~ and ~~enforce~~maintain intellectual property protection for our product candidates;

●

significant and changing government regulation;

Table of Contents

●

establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers, developing and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;

●

the timing and receipt of ~~any~~ regulatory ~~approvals;~~approvals, if any; and

●

the risks disclosed in the section entitled “Risk Factors” ~~included in~~of our Annual Report.

~~Table of Contents~~

A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs, timing, and viability associated with the development of that product candidate.

We expect our research and development expenses to increase over the next several years as we continue to implement our business strategy, which includes advancing our product candidates into and through clinical development, expanding our research and development efforts, seeking regulatory approvals for any product candidates for which we successfully complete clinical studies, accessing and developing additional product candidates, and hiring additional personnel to support our research and development efforts. In addition, product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical studies. As such, we expect our research and development expenses to increase as our product candidates advance into later stages of clinical development.

General and administrative expenses

General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation. General and administrative expenses also include rent as well as professional fees for legal, consulting, accounting, and audit services.

In the future, we expect that our general and administrative expenses will increase as we continue to support our research and development and the potential commercialization of our product candidates, if approved. We also anticipate that we will incur increased accounting, audit, legal, tax, regulatory, compliance, and director and officer insurance costs, as well as investor and public relations expenses associated with maintaining compliance with exchange listing and SEC requirements.

Other income

Other income consists primarily of the interest income earned on our cash and cash equivalents.

Results of operations

Comparison of the three months ended September 30, ~~2019~~2020 and ~~2018~~2019

The following table summarizes our results of operations for the three months ended September 30, ~~2019~~2020 and ~~2018~~2019 (in thousands):


	Three months
	ended September 30,				Increase
	2019		2018		(Decrease)

							Three months
							ended September 30,				Increase
							2020		2019		(Decrease)
Revenues:
Collaboration revenue	$	936	$	943	$	(7)	$	257	$	936	$	(679)
Operating expenses:
Research and development		11,761		11,950		(189)		6,630		11,761		(5,131)
General and administrative		4,523		3,782		741		5,050		4,523		527
Total operating expenses		16,284		15,732		552		11,680		16,284		(4,604)
Loss from operations		(15,348)		(14,789)		559		(11,423)		(15,348)		(3,925)
Other income		558		608		(50)		85		558		(473)
Net loss and comprehensive loss	$	(14,790)	$	(14,181)	$	609	$	(11,338)	$	(14,790)	$	(3,452)

Table of Contents

Collaboration revenue

Collaboration revenue was $0.3 million and $0.9 million for ~~each of~~ the three months ended September 30, 2020 and 2019 and ~~2018, and is~~was attributable to ~~the~~our research collaboration with Allergan.

~~Table~~The jointly funded research activities under the research collaboration and the associated payments by Allergan came to their contractual conclusion in the third quarter of ~~Contents~~

2020.

Research and development expenses

The following table summarizes our research and development expenses incurred during the three months ended September 30, ~~2019~~2020 and ~~2018~~2019 (in thousands):


	Three months
	ended September 30,				Increase
	2019		2018		(Decrease)

							Three months
							ended September 30,				Increase
							2020		2019		(Decrease)
NYX-2925	$	3,755	$	5,791	$	(2,036)	$	1,324	$	3,755	$	(2,431)
NYX-783		1,765		360		1,405		1,959		1,765		194
NYX-458		1,412		867		545		441		1,412		(971)
Preclinical research and discovery programs		1,590		1,710		(120)		689		1,590		(901)
Personnel and related costs		3,239		3,222		17		2,217		3,239		(1,022)
Total research and development expenses	$	11,761	$	11,950	$	(189)	$	6,630	$	11,761	$	(5,131)

Research and development expenses were $6.6 million for the three months ended September 30, 2020, compared to $11.8 million for the three months ended September 30, ~~2019, compared to $12.0 million for the three months ended September 30, 2018.~~2019. The decrease of ~~$0.2~~$5.2 million was primarily due to the following:

●

approximately ~~$2.0~~$2.4 million decrease ~~for clinical, regulatory, and drug product costs~~ related to the temporary suspension of enrollment in our two chronic pain studies of NYX-2925 ~~as a result of the completion of~~– in September 2020 we recommenced study activities in our ~~enrollment efforts for~~Phase 2b clinical study in patients with fibromyalgia and expect to recommence our Phase 2 clinical study in patients with painful DPN in ~~2018~~the fourth quarter of 2020;

●

approximately $1.0 million decrease for lower employee headcount costs and ~~enrollment efforts for our~~related support costs in 2020 compared to 2019;

●

approximately $1.0 million decrease related to the suspension of the exploratory Phase 2 ~~clinical~~ study of NYX-458 in patients with fibromyalgia completed in the first half of 2019 partially offset by activities relating in the initiation of two Phase 2 chronic pain studies, and two Phase 1 exploratory pharmacodynamic clinical studies that commenced and completed in 2018;

~~approximately $1.4 million increase for clinical, regulatory, and drug product costs related to the ongoing development of NYX-783 for the treatment of PTSD;~~

~~approximately $0.5 million increase for clinical, regulatory and drug product costs related to the ongoing development of NYX-458 for the treatment of~~ Parkinson’s disease cognitive ~~impairment;~~

impairment due to the COVID-19 pandemic; and

●

approximately ~~$0.1~~$0.9 million decrease ~~for costs associated with~~related to temporary delays in our preclinical research efforts with external research ~~organizations; and~~

organizations due to the COVID-19 pandemic.

~~approximately less than $0.1 million increase for costs related to employee compensation and related support.~~

General and administrative expenses

General and administrative expenses were $5.0 million for the three months ended September 30, 2020, compared to $4.5 million for the three months ended September 30, ~~2019, compared~~2019. The increase of $0.5 million was due to ~~$3.8~~non-cash stock based-compensation expenses, insurance costs to support ongoing business operations, professional fees, and patent costs.

Other income

We recorded $0.1 million and $0.6 million of other income for the three months ended September 30, ~~2018. The increase of $0.7 million~~2020 and 2019, respectively. This decrease was primarily driven by increased costs related to employee compensation due to increased headcount, professional fees and insurance costs to support ongoing business operations, patent-related matters, and to comply with obligations associated with being a ~~publicly traded company.~~

~~Other income~~

~~We recorded $0.6 million of other income for each of the three months ended September 30, 2019 and 2018. This was due to~~decrease in interest income earned on our cash and cash equivalents.

2322

Table of Contents

Comparison of the nine months ended September 30, ~~2019~~2020 and ~~2018~~2019

The following table summarizes our results of operations for the nine months ended September 30, ~~2019~~2020 and ~~2018~~2019 (in thousands):


	Nine months
	ended September 30,				Increase
	2019		2018		(Decrease)

							Nine months
							ended September 30,				Increase
							2020		2019		(Decrease)
Revenues:
Collaboration revenue	$	2,751	$	3,893	$	(1,142)		1,564		2,751		(1,187)
Grant revenue		—		1,642		(1,642)
Total revenues		2,751		5,535		(2,784)
Operating expenses:
Research and development		33,732		37,860		(4,128)		26,049		33,732		(7,683)
General and administrative		14,419		7,853		6,566		14,719		14,419		300
Total operating expenses		48,151		45,713		2,438		40,768		48,151		(7,383)
Loss from operations		(45,400)		(40,178)		5,222		(39,204)		(45,400)		(6,196)
Other income		1,768		990		778		639		1,768		(1,129)
Net loss and comprehensive loss	$	(43,632)	$	(39,188)	$	4,444	$	(38,565)	$	(43,632)	$	(5,067)

Collaboration revenue

Collaboration revenue was ~~$2.8~~$1.6 million and ~~$3.9~~$2.8 million for the nine months ended September 30, ~~2019~~2020 and ~~2018,~~2019, respectively, and iswas attributable to the research collaboration with Allergan. The ~~decrease was predominantly attributable~~jointly funded research activities under the research collaboration and the associated payments by Allergan came to ~~the $1.0 million associated with Allergan’s exercise of its option in May 2018 to acquire exclusive rights to develop and commercialize AGN-241751.~~

~~Grant revenue~~

The decrease of $1.6 million of grant revenue was primarily driven by a reduction in our research and development costs incurred under our grants from the U.S. government as the activities underpinning our outstanding grants were completedtheir contractual conclusion in the ~~first half~~third quarter of ~~2018, and accordingly, we did not generate any grant-related revenue for the nine months ended September 30, 2019.~~ 2020.

Research and development expenses

The following table summarizes our research and development expenses incurred during the nine months ended September 30, ~~2019~~2020 and ~~2018~~2019 (in thousands):


	Nine months
	ended September 30,				Increase
	2019		2018		(Decrease)

							Nine months
							ended September 30,				Increase
							2020		2019		(Decrease)
NYX-2925	$	7,717	$	17,355	$	(9,638)	$	8,224	$	7,717	$	507
NYX-783		5,518		2,654		2,864		5,758		5,518		240
NYX-458		4,886		2,385		2,501		3,046		4,886		(1,840)
Preclinical research and discovery programs		4,685		5,804		(1,119)		2,471		4,685		(2,214)
Personnel and related costs		10,926		9,662		1,264		6,550		10,926		(4,376)
Total research and development expenses	$	33,732	$	37,860	$	(4,128)	$	26,049	$	33,732	$	(7,683)

Research and development expenses were $26.0 million for the nine months ended September 30, 2020, compared to $33.7 million for the nine months ended September 30, ~~2019, compared to $37.9 million for the nine months ended September 30, 2018.~~2019. The decrease of ~~$4.2~~$7.7 million was primarily due to the following:

●

approximately $4.4 million decrease due to lower employee headcount costs and related support costs in 2020 compared to 2019;

●

approximately ~~$9.6~~$2.2 million decrease for ~~clinical, regulatory, and drug product~~ costs ~~related to NYX-2925, as a result of the completion of~~associated with our ~~enrollment~~preclinical research efforts ~~for our Phase 2 clinical study in patients~~ with ~~painful DPN in~~

external research organizations;

~~Table of Contents~~

~~2018 and for our Phase 2 clinical study in patients with fibromyalgia in the first half of 2019, and two Phase 1 exploratory pharmacodynamic clinical studies that were commenced and completed in 2018;~~

●

approximately ~~$2.9~~$1.8 million ~~increase for clinical, regulatory, and drug product costs related to the ongoing development and movement into Phase 2 clinical development of NYX-783 for the treatment of PTSD in 2019;~~

~~approximately $2.5 million increase for clinical, regulatory and drug product costs~~decrease related to the ongoing development of NYX-458 for the treatment of Parkinson’s disease cognitive ~~impairment;~~

impairment, including the suspension of the exploratory Phase 2 study of NYX-458 due to the COVID-19 pandemic; and

●

offset by approximately $0.5 million increase related to the ongoing development of NYX-2925 for the treatment of chronic pain, as a result of the recommencement of two Phase 2b chronic pain studies in 2020 –

Table of Contents

~~approximately $1.1 million decrease for costs associated with our preclinical research efforts with external research organizations; and~~

~~approximately $1.3 million increase for costs related to employee compensation~~one in patients with painful DPN and ~~related support.~~

one in patients with fibromyalgia – which offset the completion of our initial Phase 2 clinical studies in these indications in 2019.

General and administrative expenses

General and administrative expenses were $14.7 million for the nine months ended September 30, 2020, compared to $14.4 million for the nine months ended September 30, ~~2019, compared to $7.9 million for the nine months ended September 30, 2018.~~2019. The increase of ~~$6.5~~$0.3 million was ~~driven by increased costs~~due to a $1.6 million increase related to employee ~~compensation due to increased headcount, increased professional fees~~non-cash stock based-compensation expenses and insurance costs to support ongoing business operations ~~patent-related matters,~~offset by a decrease of $1.3 million related to reduced employee headcount, professional fees, and ~~to comply with obligations associated with being a publicly traded company.~~patent costs.

Other income

We recorded ~~$1.8~~$0.6 million of other income for the nine months ended September 30, ~~2019,~~2020, compared to ~~$1.0~~$1.8 million for the nine months ended September 30, ~~2018.~~2019. This decrease was ~~due to increased~~primarily driven by a decrease in interest income earned on our cash and cash equivalents.

Liquidity and capital resources

From our inception through September 30, ~~2019,~~2020, we have incurred significant operating losses and have funded our operations to date through proceeds from collaborations, grants, sales of convertible preferred stock, IPO and follow-on public offering and our ~~IPO.~~ATM Offering. We have generated limited revenue to date from a research collaboration agreement with Allergan, a development services agreement with Allergan, and research and development grants from the U.S. government. The jointly funded research activities under the research collaboration agreement with Allergan, as well as associated payments by Allergan to us, came to their contractual conclusion in accordance with the agreement in the third quarter of 2020.

On June 25, 2018, we completed our IPO, pursuant to which we issued and sold 7,359,998 shares of our common stock at a price of $16.00 per share, which included 959,999 shares sold pursuant to the exercise of the underwriters’ option to purchase additional shares. We received $106.5 million of proceeds, net of underwriting discounts and commissions and other offering expenses.

On July 1, 2019, we entered into a Sales Agreement, ~~(the “Sales Agreement”)~~or the Sales Agreement, with Cowen and Company, LLC, ~~(“Cowen”),~~or Cowen, pursuant to which we may issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $50.0 million through Cowen as sales agent. Cowen may sell common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or through the Nasdaq Global Select Market or any other existing trade market for the common stock, in negotiated transactions at market prices prevailing at the time of sale or at prices related to prevailing market prices, or any other method permitted by law. Cowen will be entitled to receive 3.0% of the gross sales price per share of common stock sold under the Sales Agreement. ~~As of~~During the nine months ended September 30, ~~2019, no~~2020, 1,491,482 shares of common stock have been issued and sold pursuant to the Sales ~~Agreement.~~Agreement at a weighted-average price of $3.89 per share. During the nine months ended September 30, 2020, we received $5.7 million of net proceeds after deducting sales commissions and other offering expenses.

On January 14, 2020, we completed a follow-on public offering of our common stock pursuant to an effective registration statement on Form S-3. We sold an aggregate of 11,691,666 shares of common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share. Net proceeds from the offering were approximately $33.3 million after deducting underwriting discounts and commissions as well as other offering expenses.

On October 26, 2020, we completed a follow-on public offering of its common stock pursuant to an effective registration statement on Form S-3. We sold an aggregate of 16,100,000 shares of common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share. Net proceeds from

Table of Contents

the offering were approximately $45.1 million after deducting underwriting discounts and commissions as well as estimated offering expenses.

As of September 30, ~~2019,~~2020, we had cash and cash equivalents of $~~114.2~~ ~~million.~~$103.8 million, not including the proceeds from the follow-on offering of our common stock completed on October 26, 2020. We invest our cash equivalents in liquid money market accounts.

Funding requirements

Our primary uses of capital are, and we expect will continue to be, research and development ~~services,~~activities, compensation and related expenses, product manufacturing, laboratory and related supplies, legal, and other regulatory expenses, patent prosecution filing and maintenance costs for our licensed intellectual property, and general overhead costs. We expect to

~~Table of Contents~~

continue incurring significant expenses and operating losses for the foreseeable future. In addition, since the closing of our IPO, we have incurred, and expect to incur, additional costs associated with operating as a public company. We anticipate that our expenses will increase in connection with our ongoing activities, as we:

●

seek to address and recover from impacts of the COVID-19 pandemic, including delays to our product development timelines;

●

advance the clinical development of our lead product candidates;

●

continue to improve the manufacturing process for our product ~~candidates;~~candidates and manufacture clinical supplies as our development progresses;

●

continue the research and development of our preclinical product candidates;

●

seek to identify and develop additional product candidates;

●

maintain, ~~expend,~~expand, and protect our intellectual property portfolio; and

●

improve our operational, financial, and management systems to support our clinical development and other operations.

Outlook

Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our cash and cash equivalents as of September 30, ~~2019~~2020 will be sufficient to fund our operations for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

We do not expect to generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate, which we expect will take a number of years and the outcome of which is uncertain, or enter into collaborative agreements with third parties, the timing of which is largely beyond our control and may never occur. We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future, which we may obtain through one or more equity offerings, debt financings, or other third-party funding, including potential strategic alliances and licensing or collaboration arrangements. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at ~~all.~~all, including as a result of the COVID-19 pandemic. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our current product candidates, or any additional product candidates, if developed. The amount and timing of our future funding requirements will depend on many factors, including the effects of the COVID-19 pandemic, our ability to timely and successfully enroll subjects in our clinical studies and the pace and results of our preclinical and clinical development efforts. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.

Table of Contents

Cash flows

The following table summarizes our sources and uses of cash for each of the nine months ended September 30, ~~2019~~2020 and ~~2018~~2019 (in thousands):


	Nine months ended
	September 30,
	2019		2018

					Nine months ended
					September 30,
					2020		2019
Net cash provided by (used in):
Operating activities	$	(36,627)	$	(32,465)	$	(34,443)	$	(36,627)
Investing activities		(43)		(391)		(214)		(43)
Financing activities		101		106,316		39,544		101
Net (decrease) increase in cash, cash equivalents and restricted cash	$	(36,569)	$	73,460
Net increase (decrease) in cash, cash equivalents and restricted cash					$	4,887	$	(36,569)

Operating activities

~~During~~For the nine months ended September 30, 2020, compared to the same period in 2019, ~~our~~the $2.2 million decrease in net cash used in operating activities was primarily due to a $5.1 million decrease in our net loss ~~of $43.6 million as we incurred increased external~~year over year, driven mostly by lower research and development ~~costs with~~expenses, a use of cash increase of $3.4 million due to changes in working capital largely driven by timing of cash paid to support our clinical ~~studies during~~research programs, offset by a $0.5 million increase in non-cash stock-based compensation expense.

Investing activities

For the nine months ended September 30, 2020, compared to the same period in 2019, ~~and increased general and administrative costs, partially offset by non-cash~~

~~Table of Contents~~

~~charges of $7.3~~the $0.2 million consisting primarily of $7.0 million in non-cash stock-based compensation and $0.3 million in depreciation and amortization. Net cash provided by changes in our operating assets and liabilities consisted of a $1.7 million use of cash driven by an increase in ~~prepaid expenses and other current assets and a decrease~~net cash used in ~~accounts payable partially offset by a $1.4 million source~~investing activities was primarily due to purchases of ~~cash driven by an increase in accrued expense and other liabilities and decrease in accounts receivable.~~ lab equipment.

~~During~~Financing activities

For the nine months ended September 30, ~~2018, our cash used~~2020, compared to the same period in ~~operating activities was primarily due to our net loss of $39.2 million as we incurred increased external research and development costs with our clinical studies during~~2019, the nine months ended September 30, 2018 and increased general and administrative costs, partially offset by non-cash charges of $2.3 million, consisting primarily of $2.0 million in stock-based compensation and $0.3 million in depreciation and amortization. Net cash provided by changes in our operating assets and liabilities consisted of a $1.0 million decrease in accounts receivable, prepaid expenses and other current assets, and accounts payable partially offset by a $4.0$39.4 million increase in ~~accrued expenses.~~

~~Investing activities~~

~~Net cash used in investing activities was less than $0.1 million during the nine months ended September 30, 2019, consisting of purchases of laboratory equipment.~~

Net cash used in investing activities was $0.4 million during the nine months ended September 30, 2018, consisting of purchases of property and equipment, primarily laboratory equipment and leasehold improvements.

~~Financing activities~~

~~Net~~net cash provided by financing activities was ~~$0.1~~primarily due to $33.3 million ~~during the nine months ended September 30, 2019, consisting~~and $5.7 million of net proceeds received from ~~the exercise of stock options offset by payment of deferred~~our January 2020 follow-on public offering ~~costs.~~

~~Net cash used in financing activities was $106.3 million during the nine months ended September 30, 2018,~~ ~~consisting of $109.5 million of IPO proceeds,~~and ATM Offering, respectively, net of underwriting discounts and commissions ~~offset by $3.0 million of~~and other offering ~~costs related to our IPO and additional costs of $0.2 million related to our Series B financing that closed in December 2017.~~expenses.

Critical accounting policies and significant judgments and estimates

This discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with United States generally accepted accounting principles. The preparation of our financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amount of assets, liabilities, revenue, costs and expenses, and related disclosures. Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations— Critical Accounting Policies and Significant Judgments and Estimates” in our Annual Report. There were no material changes to our critical accounting policies through September 30, ~~2019~~2020 from those discussed in our Annual Report.

Recent accounting pronouncements

See Note 2 to our condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Table of Contents

Contractual obligations and other commitments

For a discussion of contractual obligations and other commitments affecting us, see the discussion under the heading ~~“Management~~“Management’s Discussion and Analysis of Financial Condition and Results of Operations – Contractual obligations and other commitments” included in our Annual Report.

There have ~~been~~ not been any material changes since December 31, ~~2018~~2019 to the Company’s contractual obligations and other commitments.

~~Table of Contents~~

JOBS Act accounting election

Under Section 107(b) of the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act, an “emerging growth company” can delay the adoption of new or revised accounting standards until such time as those standards would apply to private companies. We intend to rely on this exemption. There are other exemptions and reduced reporting requirements provided by the JOBS Act that we are currently evaluating. For example, as an “emerging growth company,” we are exempt from Sections 14A(a) and (b) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would otherwise require us to (1) submit certain executive compensation matters to shareholder advisory votes, such as “say-on-pay,” “say-on-frequency,” and “golden parachutes;” and (2) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of our chief executive officer’s compensation to our median employee compensation. We also intend to rely on an exemption from the rule requiring us to provide an auditor’s attestation report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002. We will continue to remain an “emerging growth company” until the earliest of the following: (1) the last day of the fiscal year following the fifth anniversary of the date of the completion of our IPO; (2) the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.07 billion; (3) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

Off-balance sheet arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Information requested by this Item 3. Quantitative and Qualitative Disclosures about Market Risk is not applicable as we are electing scaled disclosure requirements available to smaller reporting companies with respect to this Item.

Item 4. Controls and Procedures.

The Company has established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Management recognizes that any

Table of Contents

controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective at the reasonable assurance level as of September 30, ~~2019.~~

~~Table of Contents~~

2020.

Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended September 30, ~~2019~~2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

As of September 30, 2020, we have not experienced any material impact to our internal control over financial reporting due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 pandemic on our internal controls to minimize the impact on their design and operating effectiveness.

2928

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may be involved in lawsuits, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters which arise in the ordinary course of business. While the outcome of any such proceedings cannot be predicted with certainty, as of September 30, ~~2019,~~2020, we were not party to any legal proceedings that we would expect to have a material adverse impact on our financial position, results of operations, or cash flow.

Item 1A. Risk Factors.

The discussion of our business and operations in this report should be read together with the risk factors contained in Item 1A of our Annual Report and in our other filings with the SEC, which describe various risks and uncertainties to which we are or may become subject. These risks and uncertainties have the potential to affect our business, financial condition, results of operations, cash flows, strategies, or prospects in a material and adverse manner. There are no material changes from the risk factors as previously disclosed in our Annual ~~Report.~~ Report and our prior Quarterly Reports on Form 10-Q.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Unregistered Sales of Equity Securities

None.

Use of Proceeds ~~from our Public Offering of Common Stock~~

On June 25, 2018, we closed our IPO in which we issued and sold 6,399,999 shares of common stock at a public offering price of $16.00 per share, and issued an additional 959,999 shares of common stock at a price of $16.00 per share pursuant to the exercise of the underwriters’ over-allotment option. All of the shares of common stock issued and sold in our IPO were registered under the Securities Act of 1933, as amended, pursuant to a registration statement on Form S-1 (Registration No. 333-225150), which was declared effective by the SEC on June 20, 2018. J.P. Morgan, Cowen, Leerink, and BMO Capital Markets acted as joint book-running managers for the offering. The aggregate gross proceeds to us from our IPO, inclusive of the over-allotment exercise, were $117.8 million.Not applicable.

The aggregate net proceeds to us from the public offering, inclusive of the over-allotment exercise, were approximately $106.5 million, after deducting underwriting discounts and commissions and other offering expenses payable by us of approximately $3.0 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates.

~~We are holding the net proceeds from the IPO in cash and cash equivalents. As described in our Annual Report, we expect to use the net proceeds from our IPO to fund our ongoing development~~ of NYX-2925 for the treatment of chronic pain, NYX-783 for the treatment of PTSD, NYX-458 for the treatment of Parkinson’s disease cognitive impairment, to explore NMDAr-dependent biomarkers, and to discover and develop additional product candidates from our discovery platform.

Item 3. Defaults Upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

~~Table of Contents~~

Item 6. Exhibits.

EXHIBIT INDEX


Exhibit Number
~~Exhibit~~ ~~Number~~		Description
31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended
31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended
32.1*		Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		XBRL Instance Document
101.SCH*		XBRL Taxonomy Extension Schema Document

Table of Contents

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

+ The certifications furnished in Exhibit 32.1 hereto are deemed to be furnished with this Quarterly Report on Form

10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as

amended, except to the extent that the Registrant specifically incorporates it by reference.

3130

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	APTINYX INC.

Date: November 12, ~~2019~~2020	By:	/s/ Norbert G. Riedel
		Norbert G. Riedel
		President and Chief Executive Officer (Principal executive officer)

Date: November 12, ~~2019~~2020	By:	/s/ Ashish Khanna
		Ashish Khanna
		Chief Financial Officer and Chief Business Officer (Principal financial and accounting officer)

3231


		Page
PART I.	FINANCIAL INFORMATION	5
Item 1.	Condensed Financial Statements (unaudited)	5
	Balance Sheets	5
	Statements of Operations	6
	Statements of Cash Flows	7
	Statements of ~~Convertible Preferred Stock and~~ Stockholders’ ~~(Deficit)~~ Equity	8
	Notes to Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19 18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	28 27
Item 4.	Controls and Procedures	28 27
PART II.	OTHER INFORMATION	30 29
Item 1.	Legal Proceedings	30 29
Item 1A.	Risk Factors	30 29
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30 29
Item 3.	Defaults Upon Senior Securities	30 29
Item 4.	Mine Safety Disclosures	30 29
Item 5.	Other Information	30 29
Item 6.	Exhibits	31 29
Signatures		32 31